Free Newsletter
Glaxo wins European contract for Cervarix
GlaxoSmithKline has won another European contract for the cervical cancer vaccine Cervarix. The Dutch government selected Cervarix for a new program to vaccinate all girls aged 12 with a catch-up program for girls aged 13 to 16 in the second half of 2009. In the first year some 350,000 Dutch girls will get the jab.
Cervarix won out over Merck's Gardasil in the Netherlands, but has yet to be approved in the United States. That makes European market penetration vital for Glaxo.
"We are delighted with this decision and the fact that since Cervarix received European approval it has been selected as the cervical cancer vaccine for more than half of eligible tenders across Europe," said Eddie Gray, president of Pharmaceuticals Europe for GSK. "We look forward to working with the Netherlands Vaccine Institute." Globally, cervical cancer is the second leading cause of cancer death among women.
- check out GSK's release
Related Articles:
Glaxo ready to wait for late-stage Cervarix data
UK health officials in cancer vaccine fight
Cervarix data demonstrates prolonged protection
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: